What is Esperion Therapeutics's finished goods?

Esperion Therapeutics (ESPR) reported finished goods of $3.14M in Q1 2026.

How has Esperion Therapeutics's finished goods changed year-over-year?

Esperion Therapeutics's finished goods decreased by 42.1% year-over-year, from $5.41M to $3.14M.

What is the long-term trend for Esperion Therapeutics's finished goods?

Over 5 years (2020 to 2025), Esperion Therapeutics's finished goods has grown at a 41.6% compound annual growth rate (CAGR), from $320K to $1.82M.

Esperion Therapeutics ESPR Finished goods

Finished goods at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's finished goods?: Esperion Therapeutics (ESPR) reported finished goods of $3.14M in Q1 2026.
How has Esperion Therapeutics's finished goods changed year-over-year?: Esperion Therapeutics's finished goods decreased by 42.1% year-over-year, from $5.41M to $3.14M.
What is the long-term trend for Esperion Therapeutics's finished goods?: Over 5 years (2020 to 2025), Esperion Therapeutics's finished goods has grown at a 41.6% compound annual growth rate (CAGR), from $320K to $1.82M.